A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance (RPX2014/RPX7009) in Subjects With Renal Insufficiency
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2015
At a glance
- Drugs Meropenem/vaborbactam (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Rempex Pharmaceuticals
- 10 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 28 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Feb 2014 Status changed from not yet recruiting to recruiting according to ClinicalTrials.gov record.